We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio NEW ORLEANS — Inhibition of PCSK9 ...

ATLANTA, GA—Using inclisiran (Leqvio; Novartis) as soon as possible in the care of patients with atherosclerotic cardiovascular disease (ASCVD) is associated with sustained lowering of LDL cholesterol ...

PARIS — Phase 3 trial results show a 50% reduction in low-density lipoprotein cholesterol (LDL) levels with a twice-yearly subcutaneous injection of the novel RNA agent inclisiran (The Medicines ...

Healthcare systems are slowly gearing up for the commercial availability of inclisiran (Leqvio; Novartis), a therapy given just twice a year in the doctor’s office to lower LDL-cholesterol levels. The ...

Inclisiran inhibits hepatic synthesis of proprotein convertase subtilisin–kexin type 9. Previous studies suggest that inclisiran might provide sustained reductions in low-density lipoprotein (LDL) ...

PHILADELPHIA — A second phase 3 trial with the novel lipid-lowering agent inclisiran (The Medicines Company), which is administered just twice yearly as a subcutaneous injection, have shown impressive ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. PARIS — Inclisiran, an investigational ...

Share on Pinterest The newly approved drug could save thousands of lives in the U.K. alone. Coolpicture/Getty Images About half of the U.K.’s adult population currently has cholesterol levels above ...

In a previous study, a single injection of inclisiran, a chemically synthesized small interfering RNA designed to target PCSK9 messenger RNA, was found to produce sustained reductions in low-density ...